India’s very own indigenously developed COVID-19 vaccine, Covaxin has completed another trial phase in Kanpur. The trial included administering the vaccine to 1,000 volunteers across the city from different walks of life. This phase of the trail was completed on December 21 at Prakhar Hospital in Kanpur.
The first dose of indigenously developed coronavirus vaccine, Covaxin, has been successfully administered to 1,000 volunteers, as part of phase III trial at Kanpur’s Prakhar Hospital. Now, for the next phase of the Covaxin vaccine trial, the same 1,000 volunteers will be administered with the vaccine before January 03, 2021. Dr JS Kushwaha, the principal investigator at Prakhar hospital, said that the first dose of Covaxin was administered successfully to all the volunteers and there was no report of any reaction or health issue faced by them.
The next phase of Covaxin trials in Kanpur is on
To successfully administer the vaccine to the 1,000 volunteers, it took the hospital and the staff a total of 17 days. The volunteers were observed before and after the vaccine was given to them, so as to properly gauge the impact of the vaccine on the human body. Now, the next phase of the trial is set to begin soon and the volunteers have so far have not shown any negative or side effects.
Here’s what you need to know about Covaxin
Covaxin vaccine has been created by India’s very own Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). As of now, hospitals are awaiting emergency approval for the usage of the vaccine from the Drug Controller General of India.
According to research on primates, Covaxin, the vaccine doesn’t just fight off the COVID virus, it makes immune systems stronger, which can then fight off many diseases, the primary one being the SARS CoV-2 strain of the virus.
Interestingly, the Covaxin trials aren’t the only vaccination trials going on in Kanpur. Earlier this month, a total of 13 volunteers were given the Sputnik V- a Russian grown vaccine for the COVID-19 virus.
